NCT04047186 is a Phase 2 clinical trial of Tislelizumab Injection in Multiple Pulmonary Nodules, sponsored by XiangNing Fu.

Who is sponsoring NCT04047186?

NCT04047186 is sponsored by XiangNing Fu.

What drugs are being tested in NCT04047186?

Interventions in NCT04047186: Tislelizumab Injection.

What condition does NCT04047186 study?

NCT04047186 studies Multiple Pulmonary Nodules.

Is NCT04047186 still recruiting?

NCT04047186 is currently completed. Last updated 23 September 2025.

Last reviewed 2025-09-23 · How we verify

NCT04047186

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Completed Phase 2 Last updated 23 September 2025

What this trial tests

Phase 2 trial testing Tislelizumab Injection in Multiple Pulmonary Nodules in 12 participants. Completed in 30 May 2025.

Timeline

1 July 2019

Primary endpoint
31 December 2024

30 May 2025

Quick facts

Lead sponsor	XiangNing Fu
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 July 2019
Primary completion	31 December 2024
Estimated completion	30 May 2025
Sites	1 location across China

Drugs / interventions tested

Tislelizumab Injection — full drug profile →

Conditions studied

Multiple Pulmonary Nodules — all drugs for Multiple Pulmonary Nodules →

Sponsor

XiangNing Fu

Who can join

18 and older, any sex, with Multiple Pulmonary Nodules. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a pilot study

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.
Zhang C, Yin K, Liu SY, Yan LX, et al · · 2021 · cited 56× · PMID 33820821 · DOI 10.1136/jitc-2020-002312
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
Godoy LA, Chen J, Ma W, Lally J, et al · · 2023 · cited 34× · PMID 36650586 · DOI 10.1186/s40364-022-00444-7
Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine.
Zhao L, Liu C, Xie G, Wu F, et al · · 2020 · cited 33× · PMID 33116891 · DOI 10.2147/cmar.s268081
Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer.
Chiang CL, Tsai PC, Yeh YC, Wu YH, et al · · 2022 · cited 23× · PMID 35008406 · DOI 10.3390/cancers14010242
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
Qiu B, Cai K, Chen C, Chen J, et al · · 2021 · cited 17× · PMID 34733623 · DOI 10.21037/tlcr-21-634
Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.
Yu F, Peng M, Bai J, Zhu X, et al · · 2022 · cited 15× · PMID 36029220 · DOI 10.1002/ijc.34238
Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.
Qu R, Ye F, Hu S, Wang B, et al · · 2023 · cited 15× · PMID 35986758 · DOI 10.1007/s00432-022-04289-3
Expert consensus on perioperative treatment for non-small cell lung cancer.
Duan J, Tan F, Bi N, Chen C, et al · · 2022 · cited 13× · PMID 35958323 · DOI 10.21037/tlcr-22-527

Verify or expand the search:

Other trials of Tislelizumab Injection

Trials testing the same drug.

NCT07390383 — A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] · Phase 2 · not yet recruiting
NCT07331155 — A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] · Phase 2 · recruiting
NCT06883552 — An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients · Phase 2 · not yet recruiting
NCT06563245 — Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · Phase 2, PHASE3 · recruiting
NCT06379087 — Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC · Phase 2 · recruiting

Other recruiting trials for Multiple Pulmonary Nodules

Currently open trials in the same condition.

NCT04574518 — Teachable Moment to Opt-out of Tobacco: Interactive Voice Response Quit Line for Veteran Active Smokers With Lung Nodule · NA · active not recruiting
NCT05171491 — LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04047186 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by XiangNing Fu
Last refreshed: 23 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04047186.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing